Loading video formats, please wait... If the video buffers too much, choose a lower quality from the selector above.
HIMS Soars
Description
Hims & Hers Health shares rose 9.63% premarket after backing FDA plans to ease peptide therapy restrictions. Health Secretary RFK Jr. said the FDA will review select peptides in July with potential removal from the high-risk list. The company sees new revenue opportunities in regulated peptide channels. BofA cut its price target to $21, citing 2026 EBITDA pressure as GLP-1 contribution declines.
Discover More
More from User
00:56
UAE Expands Offshore Gas
Benzinga
00:54
GM Raises Profit Outlook
Benzinga
01:05
3M Surges on Earnings Beat
Benzinga
00:56
Big Food Stocks Lose Appeal
Benzinga
00:56
Lyons Magnus Sold For $1B
Benzinga
00:55
Novo Sues Lilly Over Ads
Benzinga
Related Videos
04:15
Novo Nordisk reports Q1 profits o $3.65 BN as demand for weightloss drug soars
CGTN Europe
01:39:48
Hate Him, Yet My Heart Beats Only For Hims
Rough.Render
05:42
EUA ng Pfizer vaccines para sa mga edad 5-11, aprubado na ng FDA; Pilipinas, tumaas ang puwesto sa COVID-19 response ranking ng Bloomberg
PTVPhilippines
00:30
But de Hims - Team A
LE FIVE 4PADEL
03:44
Hims, Dopia - Bad Bitch
houseyounite
00:30
But de Hims - Team A
LE FIVE 4PADEL